QURE
Price
$15.72
Change
-$0.74 (-4.50%)
Updated
Dec 18, 04:59 PM (EDT)
75 days until earnings call
RPRX
Price
$24.47
Change
-$0.65 (-2.59%)
Updated
Dec 18, 04:59 PM (EDT)
56 days until earnings call
Ad is loading...

QURE vs RPRX

Header iconQURE vs RPRX Comparison
Open Charts QURE vs RPRXBanner chart's image
uniQure
Price$15.72
Change-$0.74 (-4.50%)
Volume$39.58K
CapitalizationN/A
Royalty Pharma
Price$24.47
Change-$0.65 (-2.59%)
Volume$69.62K
CapitalizationN/A
QURE vs RPRX Comparison Chart
Loading...
QURE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RPRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
QURE vs. RPRX commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is QURE is a Buy and RPRX is a Hold.

COMPARISON
Comparison
Dec 19, 2024
Stock price -- (QURE: $16.46 vs. RPRX: $25.12)
Brand notoriety: QURE and RPRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: QURE: 65% vs. RPRX: 111%
Market capitalization -- QURE: $802.31M vs. RPRX: $11.16B
QURE [@Biotechnology] is valued at $802.31M. RPRX’s [@Biotechnology] market capitalization is $11.16B. The market cap for tickers in the [@Biotechnology] industry ranges from $482.1B to $0. The average market capitalization across the [@Biotechnology] industry is $2.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

QURE’s FA Score shows that 0 FA rating(s) are green whileRPRX’s FA Score has 2 green FA rating(s).

  • QURE’s FA Score: 0 green, 5 red.
  • RPRX’s FA Score: 2 green, 3 red.
According to our system of comparison, RPRX is a better buy in the long-term than QURE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

QURE’s TA Score shows that 6 TA indicator(s) are bullish while RPRX’s TA Score has 4 bullish TA indicator(s).

  • QURE’s TA Score: 6 bullish, 4 bearish.
  • RPRX’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, QURE is a better buy in the short-term than RPRX.

Price Growth

QURE (@Biotechnology) experienced а +7.58% price change this week, while RPRX (@Biotechnology) price change was -1.84% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.67%. For the same industry, the average monthly price growth was -1.92%, and the average quarterly price growth was +0.65%.

Reported Earning Dates

QURE is expected to report earnings on Mar 03, 2025.

RPRX is expected to report earnings on Feb 12, 2025.

Industries' Descriptions

@Biotechnology (-6.67% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RPRX($11.2B) has a higher market cap than QURE($802M). QURE YTD gains are higher at: 143.131 vs. RPRX (-7.794). RPRX has higher annual earnings (EBITDA): 1.92B vs. QURE (-157.84M). RPRX has more cash in the bank: 1.76B vs. QURE (435M). QURE has less debt than RPRX: QURE (67.6M) vs RPRX (7.61B). RPRX has higher revenues than QURE: RPRX (2.27B) vs QURE (28.6M).
QURERPRXQURE / RPRX
Capitalization802M11.2B7%
EBITDA-157.84M1.92B-8%
Gain YTD143.131-7.794-1,836%
P/E RatioN/A9.63-
Revenue28.6M2.27B1%
Total Cash435M1.76B25%
Total Debt67.6M7.61B1%
FUNDAMENTALS RATINGS
QURE vs RPRX: Fundamental Ratings
QURE
RPRX
OUTLOOK RATING
1..100
3020
VALUATION
overvalued / fair valued / undervalued
1..100
75
Overvalued
1
Undervalued
PROFIT vs RISK RATING
1..100
10031
SMR RATING
1..100
9892
PRICE GROWTH RATING
1..100
3473
P/E GROWTH RATING
1..100
92100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RPRX's Valuation (1) in the Pharmaceuticals Major industry is significantly better than the same rating for QURE (75) in the Biotechnology industry. This means that RPRX’s stock grew significantly faster than QURE’s over the last 12 months.

RPRX's Profit vs Risk Rating (31) in the Pharmaceuticals Major industry is significantly better than the same rating for QURE (100) in the Biotechnology industry. This means that RPRX’s stock grew significantly faster than QURE’s over the last 12 months.

RPRX's SMR Rating (92) in the Pharmaceuticals Major industry is in the same range as QURE (98) in the Biotechnology industry. This means that RPRX’s stock grew similarly to QURE’s over the last 12 months.

QURE's Price Growth Rating (34) in the Biotechnology industry is somewhat better than the same rating for RPRX (73) in the Pharmaceuticals Major industry. This means that QURE’s stock grew somewhat faster than RPRX’s over the last 12 months.

QURE's P/E Growth Rating (92) in the Biotechnology industry is in the same range as RPRX (100) in the Pharmaceuticals Major industry. This means that QURE’s stock grew similarly to RPRX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
QURERPRX
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
69%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
60%
Momentum
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
72%
MACD
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
67%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
72%
Bearish Trend 2 days ago
64%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
73%
Bearish Trend 2 days ago
65%
Advances
ODDS (%)
Bullish Trend 3 days ago
73%
Bullish Trend 2 days ago
51%
Declines
ODDS (%)
Bearish Trend 15 days ago
87%
Bearish Trend 8 days ago
65%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
68%
Aroon
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
66%
View a ticker or compare two or three
Ad is loading...
QURE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RPRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
GNMA43.37N/A
N/A
iShares GNMA Bond ETF
FBOT28.70-0.02
-0.06%
Fidelity Disruptive Automation ETF
DWMF27.30-0.05
-0.20%
WisdomTree International Mltfctr
FDLO62.19-0.16
-0.26%
Fidelity Low Volatility Factor ETF
VUG426.93-1.18
-0.28%
Vanguard Growth ETF

QURE and

Correlation & Price change

A.I.dvisor indicates that over the last year, QURE has been loosely correlated with PIRS. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if QURE jumps, then PIRS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To QURE
1D Price
Change %
QURE100%
-5.40%
PIRS - QURE
60%
Loosely correlated
N/A
CMRX - QURE
58%
Loosely correlated
-3.44%
HOOK - QURE
44%
Loosely correlated
-1.84%
AXON - QURE
42%
Loosely correlated
-2.09%
NAMS - QURE
40%
Loosely correlated
+7.69%
More

RPRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, RPRX has been loosely correlated with AXON. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if RPRX jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RPRX
1D Price
Change %
RPRX100%
+0.48%
AXON - RPRX
48%
Loosely correlated
-2.09%
ADAP - RPRX
33%
Loosely correlated
+1.35%
MDGL - RPRX
31%
Poorly correlated
-1.58%
ARRY - RPRX
30%
Poorly correlated
+6.01%
QURE - RPRX
29%
Poorly correlated
-5.40%
More